Neuraxis, INC

Insider Trading Arrangements and Policies

On September 10, 2026, Brian Carrico, the Company’s President and Chief Executive Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Rule 10b5-1(c) Trading Plan”). The Rule 10b5-1(c) Trading Plan provides for the potential sale of up to 36,000 shares of the Company’s common stock, subject to the terms and conditions of the plan, with proceeds expected to be used for income taxes incurred on the vesting of restricted stock units. The plan is scheduled to expire on December 11, 2027, unless earlier terminated in accordance with its terms. The Rule 10b5-1(c) Trading Plan was adopted during an open trading window.

On September 10, 2026, Dr. Thomas Carrico, the Company’s Chief Regulatory, Compliance and Privacy Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Rule 10b5-1(c) Trading Plan”). The Rule 10b5-1(c) Trading Plan provides for the potential sale of up to 27,000 shares of the Company’s common stock, subject to the terms and conditions of the plan, with proceeds expected to be used for income taxes incurred on the vesting of restricted stock units. The plan is scheduled to expire on August 21, 2027, unless earlier terminated in accordance with its terms. The Rule 10b5-1(c) Trading Plan was adopted during an open trading window.

On September 10, 2026, Dr. Adrian Miranda, the Company’s Chief Medical Officer and Senior Vice President of Science and Technology, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Rule 10b5-1(c) Trading Plan”). The Rule 10b5-1(c) Trading Plan provides for the potential sale of up to 27,000 shares of the Company’s common stock, subject to the terms and conditions of the plan, with proceeds expected to be used for income taxes incurred on the vesting of restricted stock units. The plan is scheduled to expire on August 21, 2027, unless earlier terminated in accordance with its terms. The Rule 10b5-1(c) Trading Plan was adopted during an open trading window.

During the quarter ended September 30, 2026, no other director or officer of the Company adopted orterminated any “Rule 10b5-1(c) trading arrangement” or “non-Rule 10b5-1(c) trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.